Can a thymus gland protein shield dialysis patients from COVID-19?
NCT ID NCT04428008
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested whether thymalfasin, a synthetic version of a natural immune-boosting protein, could prevent COVID-19 infection in 189 kidney dialysis patients. These patients are at high risk due to weakened immune systems and frequent clinic visits. The study measured how many got infected, were hospitalized, or died.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Thymalfasin (Thymosin alpha 1, Ta1)
What this could lead to
If it works, this could point toward a way to protect vulnerable dialysis patients from COVID-19 infection.
What could go wrong
This is a small, early Phase 2 pilot trial, so results may not be definitive. The drug may not reduce infection rates or severity as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Consultants
Kansas City, Kansas, 64111, United States